# Clinical Drug with Continuous Dose Form ## Overview Clinical drugs representing a continuous dose form are modeled using *concentration* strength attributes. Clinical drugs with a *continuous* dose form using *concentration* strength represents a medicinal product based on description of 1) its precise active ingredient substances only and explicitly, 2) the stated basis of strength substance(s) with strength, expressed as concentration strength and 3) with its manufactured dose form (with the exception of reconstituted oral liquid preparations, where the administrable dose form is be used as it is the most clinically relevant). This is used for product types such as cutaneous semi-solids (without metered actuation), solutions, suspensions, creams, ointments, bulk powders and granules, topical liquids (without metered actuation) including drops, oral liquids, nebuliser liquids and liquid parenteral products. For example, * Product containing precisely zidovudine 10 milligram/1 milliliter conventional release oral solution (clinical drug) * Product containing precisely amikacin (as amikacin sulfate) 250 milligram/1 milliliter conventional release solution for injection (clinical drug) * Product containing precisely clotrimazole 10 milligram/1 gram conventional release cutaneous cream (clinical drug) * Product containing precisely mupirocin (as mupirocin calcium) 20 milligram/1 gram conventional release nasal ointment (clinical drug) ## Modeling
Stated parent763158003 |Medicinal product (product)|
Semantic tag(clinical drug)
Definition status

Defined

Exception:

  • Concepts with product strength that is "not equal to" (e.g. with product strength expressed as a range, greater than, or less than) are primitive

Attribute:

Has manufactured dose form

Range: 736542009 |Pharmaceutical dose form (dose form)|

-While the allowed range for this attribute is broader, the CD-precise continuous dose from concepts should only use <736542009 | Pharmaceutical dose form (dose form), excluding grouper concepts based on intended site (e.g. 740596000 |Cutaneous dose form (dose form)|, 385268001 |Oral dose form (dose form)|).

Cardinality: 1..1

Note This is the finished dose form that a medicinal product is presented in by the manufacturer, before any transformation into an administrable dose form has taken place.

Powder and granules for oral suspension, solution, etc., may be modeled using concentration strength and the administrable dose form.

-For example, 1145409004 |Product containing precisely amoxicillin 25 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 6.25 milligram/1 milliliter conventional release oral suspension (clinical drug)|

Attribute:

Count of base of active ingredient (attribute)

Concrete Type: Integer

Range: >#0..

Cardinality: 1..1

Relationship groupOne relationship group containing one instance of each of the following attributes is required for each precise active ingredient.
  • Has precise active ingredient

Range: <105590001 |Substance (substance) excluding concepts representing structural groupers, dispositions, or combined substances


Cardinality: 1..1 per relationship group


-The Precise Active Ingredient (PAI) cannot be modeled as a
substance hydrate or solvate unless the BoSS is expressed as
a hydrate or solvate.
-Concepts containing pancreatic enzymes will be modeled
based on the discrete enzymes; because of variability
between real clinical drugs, synonyms representing a total
amount in a particular product will not be included in the
International Release.

  • Has basis of strength substance

Range: <105590001 |Substance (substance) excluding concepts representing structural groupers, dispositions, or combined substances


Cardinality: 1..1 per relationship group

  • Has concentration strength numerator value

Concrete Type: Decimal

Range: >#0..

Cardinality: 1..1 per relationship group

  • Has concentration strength numerator unit
Range: <767524001 |Unit of measure (qualifier value)| Cardinality: 1..1 per relationship group
  • Has concentration strength denominator value

Concrete Type: Decimal

Range: >#0..

Cardinality: 1..1 per relationship group

For this pattern, the attribute value must be 1.

The denominator strength value is required for concepts in the International Release even though the value = 1, because including denominators for only some concepts negatively affects the classification results.

  • Has concentration strength denominator unit

Range: <767524001 |Unit of measure (qualifier value)|

Cardinality: 1..1 per relationship group

For Clinical drug concepts with:

-liquid dose form: the denominator unit should be 258773002 | Milliliter (qualifier value)|.

-semi-solid dose form: the denominator unit should be 258682000 | gram (qualifier value)| for weight/weight concentration and 258773002 |Milliliter (qualifier value)| for weight/volume concentration. Representing semi-solid dose forms in weight/weight concentration is preferred.

## Naming ### FSN **Where Precise active ingredient = BoSS:** * Product containing precisely \ \ \/\ \ \ (clinical drug) For example, * Product containing precisely amitriptyline hydrochloride 5 milligram/1 milliliter conventional release oral solution (clinical drug) * Product containing precisely buprenorphine 70 microgram/1 hour prolonged-release transdermal patch (clinical drug) * Product containing precisely clotrimazole 10 milligram/1 gram conventional release cutaneous cream (clinical drug) * Product containing precisely zidovudine 10 milligram/1 milliliter conventional release oral solution (clinical drug) * Product containing precisely lopinavir 80 milligram/1 milliliter and ritonavir 20 milligram/1 milliliter conventional release oral solution (clinical drug) **Where Precise active ingredient is not = BoSS:** * Product containing precisely \ (as \) \ \/\ \ \ (clinical drug) For example, * Product containing precisely amikacin (as amikacin sulfate) 250 milligram/1 milliliter conventional release solution for injection (clinical drug) * Product containing precisely mupirocin (as mupirocin calcium) 20 milligram/1 gram conventional release nasal ointment (clinical drug) ### Preferred Term **Where Single ingredient with BoSS = Precise active ingredient:** * \ \ \/\ \ \ For example, * Amitriptyline hydrochloride 5 mg/mL oral solution * Buprenorphine 70 microgram/hour prolonged-release transdermal patch * Clotrimazole 10 mg/g cutaneous cream * Zidovudine 10 mg/mL oral solution * Lopinavir 80 mg/mL and ritonavir 20 mg/mL oral solution **Where Single ingredient with BoSS is not = Precise active ingredient:** * \ (as \) \ \/\ \ \ For example, * Amikacin (as amikacin sulfate) 250 mg/mL solution for injection * Mupirocin (as mupirocin calcium) 20 mg/g nasal ointment ### Synonym Synonyms converting metric units to percent or parts per millions may be included for medical gas concepts (e.g. Helium 79% and oxygen 21% gas for inhalation, Helium 790,000 ppm and oxygen 210,000 ppm gas for inhalation). ## Exemplars ### Stated template view
### Example Concepts

Stated view for 781834001 |Product containing precisely digoxin 250 microgram/1 milliliter conventional release solution for injection (clinical drug)|

Inferred view for 781834001 |Product containing precisely digoxin 250 microgram/1 milliliter conventional release solution for injection (clinical drug)|-

Stated view for 769821007 |Product containing precisely digoxin 50 microgram/1 milliliter conventional release oral solution (clinical drug)|

Inferred view for 769821007 |Product containing precisely digoxin 50 microgram/1 milliliter conventional release oral solution (clinical drug)|.

Stated view for 396279000 |Product containing precisely betamethasone (as betamethasone valerate) 1 milligram/1 gram conventional release cutaneous ointment (clinical drug)|.

Inferred view for 396279000 |Product containing precisely betamethasone (as betamethasone valerate) 1 milligram/1 gram conventional release cutaneous ointment (clinical drug)|

Stated view for 769514000 |Product containing precisely buprenorphine 70 microgram/1 hour prolonged-release transdermal patch (clinical drug)|

Inferred view for 769514000 |Product containing precisely buprenorphine 70 microgram/1 hour prolonged-release transdermal patch (clinical drug)|.

Provide Feedback --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://docs.snomed.org/snomed-ct-specifications/snomed-ct-editorial-guide/readme/authoring/domain-specific-modeling/pharmaceutical-and-biologic-product/medicinal-product/index/clinical-drug-with-continuous-dose-form.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.